Dashboard
Manage Tickers

XGNEXAGEN INC.

Nasdaq exagen.com


$ 1.87 $ 0.23 (14.02 %)    

Tuesday, 14-May-2024 14:05:12 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 445.39 $ 0.61 (0.14 %)
DIA $ 395.28 $ 0.15 (0.04 %)
SPY $ 522.66 $ 0.48 (0.09 %)
TLT $ 90.78 $ 0.17 (0.18 %)
GLD $ 218.21 $ 0.40 (0.17 %)
$ 1.64
$ 1.87
$ 0.00 x 0
$ 0.00 x 0
$ 1.87 - $ 1.87
$ 1.30 - $ 3.92
190,777
na
29.43M
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-18-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-20-2023 12-31-2022 10-K
7 11-21-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-22-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 07-28-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-25-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-maintains-overweight-on-exagen-raises-price-target-to-7
Cantor Fitzgerald Maintains Overweight on ...
05/14/2024 12:48:37

Cantor Fitzgerald analyst Ross Osborn maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $5 to...

exagen-increases-fy24-revenue-to-at-least-55m-vs-54160m-est
Exagen Increases FY24 Revenue To At Least ...
05/13/2024 12:46:31

exagen-q1-2024-gaap-eps-019-beats-036-estimate-sales-14415m-beat-13095m-estimate
Exagen Q1 2024 GAAP EPS $(0.19) Beats $(0....
05/13/2024 12:14:45

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.2...

exagen-expects-q1-fy2024-revenue-of-13m-135m-versus-consensus-of-1149m-the-company-says-existing-cash-and-cash-equivalents-of-365m-will-be-adequate-to-meet-anticipated-cash-requirements-into-2026
Exagen Expects Q1 FY2024 Revenue Of $13M-$...
03/18/2024 12:09:20

exagen-expects-fy2024-revenue-of-approximately-54m-versus-consensus-of-5414m-for-fy2024-the-company-expects-adjusted-ebitda-will-be-better-than-negative-20m
Exagen Expects FY2024 Revenue Of Approxima...
03/18/2024 12:07:34

exagen-q4-gaap-eps-031-beats-043-estimate-sales-1377m-beat-1156m-estimate
Exagen Q4 GAAP EPS $(0.31) Beats $(0.43) E...
03/18/2024 12:03:06

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.43) by 27.9...

earnings-scheduled-for-march-18-2024
Earnings Scheduled For March 18, 2024
03/18/2024 09:57:15

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

earnings-outlook-for-exagen
Earnings Outlook For Exagen
03/15/2024 15:00:25

exagen-inc-announces-select-preliminary-full-year-2023-results-cash-balance-of-365m-as-of-december-31-2023-reaffirms-fy23-revenue-guidance-of-at-least-50m-vs-5043m-est
Exagen Inc. Announces Select Preliminary F...
01/07/2024 20:13:23

Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited fina...

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
01/05/2024 13:05:58

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
01/04/2024 21:31:07

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
12/01/2023 13:06:46

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
11/21/2023 21:31:06

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
11/20/2023 21:31:10

exagen-inc-entered-into-amendment-no-1-to-that-certain-sales-agreement-dated-september-15-2022-may-from-time-to-time-continue-to-issue-sell-shares-of-common-stock-having-an-aggregate-offering-price-of-up-to-50m
Exagen Inc Entered Into Amendment No. 1 To...
11/17/2023 21:38:57

- SEC Filing  

exagen-inc-files-for-mixed-shelf-of-up-to-150m
Exagen Inc Files For Mixed Shelf Of Up To ...
11/17/2023 21:12:18

- SEC Filing

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
11/15/2023 21:31:03

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
11/14/2023 21:31:09

exagen-inc-says-fy23-revenue-guidance-of-at-least-50m-vs-4676m-est
Exagen Inc. Says FY23 Revenue Guidance Of ...
11/13/2023 21:51:22

2023 Guidance For full year 2023 revenue, we are providing guidance of at least $50 million, which will be record annual revenu...

exagen-q3-2023-gaap-eps-031-beats-046-estimate-sales-1342m-beat-1033m-estimate
Exagen Q3 2023 Gaap EPS $(0.31) Beats $(0....
11/13/2023 21:15:37

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.46) by 32.6...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION